Brokerages Set Integra LifeSciences Holdings Co. (NASDAQ:IART) Target Price at $22.71

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) has earned a consensus rating of "Reduce" from the nine analysts that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $22.71.

A number of equities research analysts have recently weighed in on IART shares. Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Truist Financial cut their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th.

Institutional Trading of Integra LifeSciences

Several large investors have recently modified their holdings of the company. Principal Financial Group Inc. boosted its holdings in Integra LifeSciences by 18.7% during the third quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company's stock valued at $7,294,000 after acquiring an additional 63,266 shares during the period. Nordea Investment Management AB lifted its position in shares of Integra LifeSciences by 4.1% during the 4th quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company's stock worth $2,919,000 after purchasing an additional 5,032 shares during the last quarter. Romano Brothers AND Company bought a new stake in Integra LifeSciences during the 4th quarter valued at approximately $204,000. Mitsubishi UFJ Asset Management UK Ltd. acquired a new stake in Integra LifeSciences in the 4th quarter valued at approximately $204,000. Finally, Nisa Investment Advisors LLC increased its position in Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after buying an additional 2,800 shares during the period. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Stock Up 0.7 %

Shares of NASDAQ IART traded up $0.11 during mid-day trading on Friday, reaching $16.81. The company had a trading volume of 758,558 shares, compared to its average volume of 1,038,451. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -186.76, a PEG ratio of 0.73 and a beta of 1.24. The stock has a fifty day moving average of $20.51 and a two-hundred day moving average of $22.23. Integra LifeSciences has a 12-month low of $14.45 and a 12-month high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. During the same quarter in the prior year, the firm earned $0.89 EPS. The company's revenue was up 11.5% compared to the same quarter last year. As a group, equities research analysts expect that Integra LifeSciences will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.